Dear Colleagues:
As biopharmaceutical companies face increasing costs, many consider offshoring manufacturing to help reduce costs. Moreover, as biologics begin to dominate the market, for many offshoring
may be one solution to tackling the exorbitant costs related to
biologics manufacturing. Several countries in Asia, including India. are already dominant offshoring locations. India's pharmaceutical manufacturing industry is well-established in the production of generics, and many predict that it may become an important center for biologics manufacturing in the near future.
We have recently published an article in the March issue of BioPharm International entitled "India's Future as a Biologics Manufacturing Hub" (pp. 20-23) which discusses the current environment for biologics in the country, and offers a perspective on the growing trends for western collaboration. What are the factors that must be addressed by companies interested in offshoring biologics production to India? How are western collaborations creating a possible solution to the problems associated with biologics manufacturing? How can foreign companies overcome major hurdles, including the numerous language and cultural barriers? We hope you take this opportunity to read the article available via the following link, and that it provides you with new information.
As a language service provider for over fifteen years, we are well aware of the importance of native language communication. Our life science experts have translation experience in over one hundred languages, including many of the numerous Indian languages.
We welcome any inquiries or comments you may have regarding the article or our services.
Best regards, |
